title: The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth.
abstract: All nascent neoplasms probably elicit at least a weak immune reaction. However, the initial effect of the weak immune reaction on a nascent tumor is always stimulatory rather than inhibitory to tumor growth, assuming only that exposure to the tumor antigens did not antedate the initiation of the neoplasm (as may occur in some virally induced tumors). This conclusion derives from the observation that the relationship between the magnitude of an adaptive immune reaction and tumor growth is not linear but varies such that while large quantities of antitumor immune reactants tend to inhibit tumor growth, smaller quantities of the same reactants are, for unknown reasons, stimulatory. Any immune reaction must presumably be small before it can become large; hence the initial reaction to the first presentation of a tumor antigen must always be small and in the stimulatory portion of this nonlinear relationship. In mouse-skin carcinogenesis experiments it was found that premalignant papillomas were variously immunogenic, but that the carcinomas that arose in them were, presumably because of induced immune tolerance, nonimmunogenic in the animal of origin.
authors.affiliation: Department of Pathology, School of Medicine, University of Washington, 5433 South Hudson St, Seattle, WA 90118, USA. prehn@u.washington.edu
authors.forename: Richmond T
authors.initials: RT
authors.lastname: Prehn
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D000917:Antibody Formation; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D007157:Immunologic Surveillance; D051379:Mice; D010212:Papilloma / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology
chemical_list: D000951:Antigens, Neoplasm
references.citation: J Natl Cancer Inst. 1971 Sep;47(3):653-65
references.pmid: 4945592
references.citation: Prog Exp Tumor Res. 1970;13:1-27
references.pmid: 4921480
references.citation: Cancer Metastasis Rev. 1984;3(1):53-74
references.pmid: 6370420
references.citation: Immunol Rev. 2008 Apr;222:341-56
references.pmid: 18364013
references.citation: Annu Rev Med. 1988;39:63-73
references.pmid: 3285791
references.citation: Int J Immunopharmacol. 1984;6(4):299-305
references.pmid: 6480195
references.citation: Adv Cancer Res. 1975;22:261-422
references.pmid: 766581
references.citation: J Invest Dermatol. 1971 Feb;56(2):102-12
references.pmid: 4933758
references.citation: Clin Cancer Res. 1997 Jan;3(1):51-5
references.pmid: 9815537
references.citation: Br J Cancer. 1976 Mar;33(3):241-59
references.pmid: 773395
references.citation: Science. 1972 Apr 14;176(4031):170-1
references.pmid: 5014438
references.citation: Br J Cancer. 1981 Nov;44(5):753-6
references.pmid: 6459113
references.citation: J Natl Cancer Inst. 1993 Mar 17;85(6):457-64
references.pmid: 8445673
references.citation: Br J Cancer. 2009 Aug 4;101(3):379-80
references.pmid: 19638985
references.citation: Hum Exp Toxicol. 2002 Feb;21(2):91-7
references.pmid: 12102503
references.citation: JAMA. 2006 Dec 20;296(23):2823-31
references.pmid: 17179459
references.citation: Int J Cancer. 1977 May 15;19(5):670-2
references.pmid: 863545
references.citation: Br J Cancer. 2009 Aug 4;101(3):381-6
references.pmid: 19638986
references.citation: Eur Urol. 2009 Sep;56(3):512-8
references.pmid: 19559518
references.citation: Cancer Res. 1960 Dec;20:1561-72
references.pmid: 13756652
references.citation: Int J Cancer. 2003 Jun 10;105(2):249-54
references.pmid: 12673687
references.citation: Lancet. 1995 Sep 23;346(8978):796-8
references.pmid: 7674744
references.citation: AIDS Patient Care STDS. 2005 Oct;19(10):635-44
references.pmid: 16232048
references.citation: Cancer Res. 1969 Dec;29(12):2374-80
references.pmid: 5369684